IVVD Invivyd Inc

$IVVD it really is a different market. Already given back half of it's gains AH. With that said insts hold almost all of it and they may not be so quick to dump on $.25-$30 move. Some point near term this should reprice moin$3-$4 on positive news. Targets (While don't mean shit in todays world) are in the $10 range. Investors in this company have had a long road, lets hope for some feeling good new and days ahead. 🙏

$IVVD options expired Friday and did anyone else notice a large institution had puts? They also have calls. Let her rip!

$IVVD look at invyvid hiring spree. Look at the news. I believe this is big pharma try to push the stock down before the massive blownout once we have fda minutes and DECLARATION data. FDA has no reason rejecting the bla path. Just be patient.

$IVVD CEO Mark Elia rocked that conference call. These Liberty results are over the top on all metrics/end points and setup Declaration very nicely. Way oversold and a very nice opportunity to average down and accumulate.

$IVVD for biotech topline clinical data, Monday through Thursday is the normal zone, and Tuesday–Thursday tends to feel especially common. Friday releases happen, but companies generally avoid dropping major market-moving data late Friday unless timing dictates it. For IVVD specifically, their history is actually pretty useful: * Monday: Dec. 18, 2023 — positive CANOPY Phase 3 results; Feb. 3, 2025 — positive VYD2311 Phase 1/2 data. * Tuesday: Nov. 12, 2024 — CANOPY clinical data/preprints; May 27, 2025 — CANOPY publication/data; Feb. 24, 2026 — new clinical analysis. * Thursday: June 26, 2025 — full VYD2311 Phase 1/2 clinical data, released at 7:01 AM ET. * Friday: March 22, 2024 — interim CANOPY exploratory data, so they clearly will use Friday when necessary. Release? Tomorrow Friday: possible, but not my favorite Monday Sept. 28: very plausible Tuesday Sept. 29: probably my favorite Wednesday Sept. 30: extremely plausible because it’s literally the final day of Q3

$IVVD I said I wouldn't but sure might as well. anyone unsure can leave now Stop behaving like fucking arseholes ! If it all goes to Shit well now , so be it . Not every ball gets Fucked out of the park but tonight I'm swingingng anyway

$IVVD Call and commentary from Elia much more positive than the initial data release. The October DECLARATION update will be critical given the regulatory path chosen, but the accelerated approval strategy appears to have been developed through active FDA engagement, including the type C meeting in Q3. Elia also explicitly confirmed that additional participants will be enrolled in a confirmatory randomized cohort to ensure DECLARATION is sufficiently powered for the eventual clinical efficacy readout

$IVVD Many people look at this wrong. The long term lease agreement is not the catalyst for the jump. But the long term lease is a confirmation that they data they have is good and they are confident to took a long term lease and expanding the office. Thats the catalyst.

$IVVD Nothing in the business has fundamentally changed. This remains a buy + hold in this price range.

$IVVD way oversold on good data but missed the DECLARATION data which are pushed to Oct. Next catalyst: - FDA's official Type C minutes, likely within weeks - DECLARATION data, also within weeks

$IVVD THIS IS IT GUYS GOING TO $1, DATA NEXT WEEK GOING TO $5, bought 40k shares more just now

$IVVD I got way too much of this shit. I bought around $1 a month ago now probably. What is the thesis... When is our next catylsist!

$IVVD ,the word is IF ivvd is granted the DECLARATION, the stock is to spike between $1 and 3 dollars, and if the F.D.A approves the vaccine, the stock is to spike between $5 and 8 dollars between 2027 and 2028 if sales for the vaccine is successful. Or a possibility of a buy out.

$IVVD albeit a different CEO at the helm though Mark Elia was part of the equation, so maybe tomorrow…

$IVVD "Buckle those seatbelts" ​My eyes are on Oct 20th for the data drop, it's my prediction for the release date. The Phase 3 LIBERTY trial already locked in safety with VYD2311 blowing mRNA vaccines out of the water on tolerability (56.5% AEs vs 91.4%, p<0.0001). Now, the upcoming DECLARATION readout, upsized to 2,400 participants for massive statistical power, focuses on neutralizing antibody titers to trigger our FDA Accelerated Approval submission. Strong titers against circulating strains confirm VYD2311 as a dominant next-gen mAb platform. ​Strap in. $IVVD 👀🚀

$IVVD Data + BLA timeline coming, but the key is FDA agreeing on titers. Company needs cash, so expect ATM/offering on any pop

$IVVD if everyone sells in the 1.30 range this won’t run. it’s gonna go up again. my guess is earnings this runs over $1 again

$IVVD tutes still own massive shares, still a reiterated buy, pt still $10, new ceo looks good, everything is good. the market seems to not like the delayed release eventhough prelim looks good.

$IVVD $2+ on good data, if market starts pricing in the approval, we could see $3+ , Probability of succes: 75%!

$IVVD looks like it's setting itself up for a profitable pop, E.g. Institutional buy low, sell high. Typical pattern with this ticker.